Literature DB >> 10518661

Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect.

Y Kawashima1, H Yamamoto, H Takeuchi, S Fujioka, T Hino.   

Abstract

Insulin loaded PLGA nanospheres having weight mean diameters of 400 nm were prepared by the modified emulsion solvent diffusion method in water. The nanosphere recovery and the drug recovery in the nanospheres were 74.8%+/-4.71 and 46.8%+/-7.01, respectively. Eighty five percent of the drug was released from the nanospheres at the initial burst, followed by prolonged releasing of the remaining drug for a few hours in saline at 37 degrees C. The aqueous dispersions (6 mg/ml) of PLGA nanospheres were nebulized by a sieve type ultrasonic nebulizer to discrete droplets of 5 approximately 7 microm in mean diameters, 75% of which were successfully delivered into the alveolar fraction in a cascade impactor inhaled at 28.3 l/min. The nebulized PLGA nanospheres were administered via a spacer by using a constant volume respirator into the trachea of the fasted guinea pig for 20 min. After the administration of 3.9 I.U./kg insulin with the PLGA nanospheres, the blood glucose level was reduced significantly and the hypoglycemia was prolonged over 48 h, compared to the nebulized aqueous solution of insulin as a reference (6 h). This result could be attributed to the sustained releasing of insulin from the nanospheres deposited widely on to the whole of lung.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10518661     DOI: 10.1016/s0168-3659(99)00048-6

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  29 in total

1.  Comparison of diafiltration and tangential flow filtration for purification of nanoparticle suspensions.

Authors:  Gautam Dalwadi; Heather A E Benson; Yan Chen
Journal:  Pharm Res       Date:  2005-12       Impact factor: 4.200

Review 2.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

Review 3.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

4.  Rapid lymph accumulation of polystyrene nanoparticles following pulmonary administration.

Authors:  Abdul Khader Mohammad; Lenah K Amayreh; John M Mazzara; Joshua J Reineke
Journal:  Pharm Res       Date:  2012-09-20       Impact factor: 4.200

Review 5.  Long-term delivery of protein therapeutics.

Authors:  Ravi Vaishya; Varun Khurana; Sulabh Patel; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2014-09-24       Impact factor: 6.648

6.  Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.

Authors:  Sutapa Barua; Samir Mitragotri
Journal:  Nano Today       Date:  2014-04-01       Impact factor: 20.722

7.  Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights.

Authors:  Daniel J Hines; David L Kaplan
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2013       Impact factor: 4.889

8.  Evaluation of novel particles as pulmonary delivery systems for insulin in rats.

Authors:  Lucila Garcia-Contreras; Tülin Morçöl; Steve J D Bell; Anthony J Hickey
Journal:  AAPS PharmSci       Date:  2003

9.  Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.

Authors:  Jean C Sung; Danielle J Padilla; Lucila Garcia-Contreras; Jarod L Verberkmoes; David Durbin; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Pharm Res       Date:  2009-04-30       Impact factor: 4.200

10.  Conjugation with cationic cell-penetrating peptide increases pulmonary absorption of insulin.

Authors:  Leena N Patel; Jeffrey Wang; Kwang-Jin Kim; Zea Borok; Edward D Crandall; Wei-Chiang Shen
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.